Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 3 studies | 18% ± 3% |
Insufficient scRNA-seq data for expression of USP19 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 5163.04 | 1445 / 1445 | 100% | 35.16 | 183 / 183 |
ovary | 100% | 5359.61 | 180 / 180 | 100% | 46.98 | 430 / 430 |
prostate | 100% | 5214.30 | 245 / 245 | 100% | 54.07 | 502 / 502 |
skin | 100% | 5411.24 | 1809 / 1809 | 100% | 65.55 | 472 / 472 |
stomach | 100% | 4279.74 | 359 / 359 | 100% | 36.73 | 286 / 286 |
thymus | 100% | 6519.11 | 653 / 653 | 100% | 49.83 | 604 / 605 |
uterus | 100% | 6357.92 | 170 / 170 | 100% | 39.48 | 458 / 459 |
liver | 100% | 2397.16 | 226 / 226 | 100% | 27.09 | 405 / 406 |
breast | 100% | 5253.92 | 459 / 459 | 100% | 45.14 | 1114 / 1118 |
bladder | 100% | 5743.48 | 21 / 21 | 100% | 37.83 | 502 / 504 |
lung | 100% | 4208.26 | 577 / 578 | 100% | 34.42 | 1152 / 1155 |
intestine | 100% | 6003.67 | 966 / 966 | 99% | 38.79 | 523 / 527 |
kidney | 100% | 4126.78 | 89 / 89 | 99% | 32.96 | 891 / 901 |
pancreas | 99% | 2843.03 | 326 / 328 | 99% | 35.74 | 177 / 178 |
brain | 98% | 3134.21 | 2595 / 2642 | 100% | 51.76 | 705 / 705 |
adrenal gland | 100% | 6023.87 | 258 / 258 | 97% | 31.68 | 224 / 230 |
adipose | 100% | 4732.49 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4508.50 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 44.08 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 44.32 | 29 / 29 |
muscle | 100% | 8662.28 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 5845.52 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 38.45 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 18.55 | 1 / 1 |
heart | 99% | 3649.52 | 849 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 95% | 3338.62 | 883 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1904292 | Biological process | regulation of ERAD pathway |
GO_0048642 | Biological process | negative regulation of skeletal muscle tissue development |
GO_0031647 | Biological process | regulation of protein stability |
GO_0016579 | Biological process | protein deubiquitination |
GO_1900037 | Biological process | regulation of cellular response to hypoxia |
GO_0050821 | Biological process | protein stabilization |
GO_0090068 | Biological process | positive regulation of cell cycle process |
GO_0036503 | Biological process | ERAD pathway |
GO_0034976 | Biological process | response to endoplasmic reticulum stress |
GO_0005829 | Cellular component | cytosol |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005515 | Molecular function | protein binding |
GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0051879 | Molecular function | Hsp90 protein binding |
Gene name | USP19 |
Protein name | Ubiquitin carboxyl-terminal hydrolase 19 Ubiquitin specific peptidase 19 USP19 protein Ubiquitin carboxyl-terminal hydrolase 19 (EC 3.4.19.12) (Deubiquitinating enzyme 19) (Ubiquitin thioesterase 19) (Ubiquitin-specific-processing protease 19) (Zinc finger MYND domain-containing protein 9) |
Synonyms | ZMYND9 KIAA0891 |
Description | FUNCTION: Deubiquitinating enzyme that regulates the degradation of various proteins. Deubiquitinates and prevents proteasomal degradation of RNF123 which in turn stimulates CDKN1B ubiquitin-dependent degradation thereby playing a role in cell proliferation. Involved in decreased protein synthesis in atrophying skeletal muscle. Modulates transcription of major myofibrillar proteins. Also involved in turnover of endoplasmic-reticulum-associated degradation (ERAD) substrates. Regulates the stability of BIRC2/c-IAP1 and BIRC3/c-IAP2 by preventing their ubiquitination. Required for cells to mount an appropriate response to hypoxia and rescues HIF1A from degradation in a non-catalytic manner. Plays an important role in 17 beta-estradiol (E2)-inhibited myogenesis. Decreases the levels of ubiquitinated proteins during skeletal muscle formation and acts to repress myogenesis. Exhibits a preference towards 'Lys-63'-linked ubiquitin chains. . |
Accessions | ENST00000398896 ENST00000453664.5 [O94966-7] A0A8I5KT08 ENST00000693111.1 A5PL36 E7ESU0 A0A8I5KRW4 ENST00000398888.6 [O94966-1] ENST00000417901.6 [O94966-6] ENST00000398896.6 [O94966-4] ENST00000434032.6 [O94966-5] ENST00000465902.2 ENST00000698200.1 A0A590UK03 O94966 A0A8I5KXK1 ENST00000689715.1 A0A8V8TN96 ENST00000692912.1 ENST00000306026.6 A0A0A0MR08 ENST00000691288.1 A0A8I5KV50 |